Clinical Trials Logo

Metastatic Basal Cell Carcinoma clinical trials

View clinical trials related to Metastatic Basal Cell Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03610022 Completed - Clinical trials for Metastatic Basal Cell Carcinoma

Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1

OPTIVISMO-1
Start date: September 3, 2018
Phase: Phase 4
Study type: Interventional

Vismodegib (ERIVEDGE®) at the standard dose of 150 mg/day orally is indicated for the treatment of advanced Basal Cell Carcinoma (BCC) and is associated with many adverse effects. Cramps, alopecia, dysgeusia, weight loss and others observed in clinical practice, compromize compliance and often lead to treatment discontinuation. Currently, it is the only drug available in this indication. Our main objective is to assess the relationship between plasma concentrations of vismodegib, and the occurrence of adverse effects within 6 months of inclusion in the study.